Gonadotropin-releasing hormone: An update review of the antagonists versus agonists

International Journal of Urology

Volumn 19, Issue 7, 2012, Pages 594-601

  Van Poppel, Hein ^a   Klotz, Laurence ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Degarelix; Disease progression; Gonadotropin releasing hormone; PPI 149; Prostate cancer

Indexed keywords

ABARELIX; BICALUTAMIDE; DEGARELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURGERY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CONNECTIVE TISSUE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GONADORELIN RELEASE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HOT FLUSH; HUMAN; INJECTION SITE REACTION; METASTASIS; MUSCULOSKELETAL DISEASE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; URINARY TRACT INFECTION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84862767296     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.02997.x     Document Type: Review

References (45)

1. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 1001-6.
2. Thompson IM. Flare associated with LHRH-agonist therapy. Rev. Urol. 2001; 3 (Suppl 3): S10-14.
3. ®? Eur. Urol. Suppl. 2005; 4: 30-6.
4. Morote J, Orsola A, Planas J etal. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 2007; 178: 1290-5.
5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr. Oncol. 2010; 17 (Suppl 2): S72-9.
6. Chi KN, Bjartell A, Dearnaley D etal. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol. 2009; 56: 594-605.
7. Heidenreich A, Bolla M, Joniau S etal. 2011. Guidelines on prostate cancer. [Cited 8 August 2011.] Available from URL:
8. Sharifi N, Dahut WL, Steinberg SM etal. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005; 96: 985-9.
9. Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 2005; 96 (Suppl 2): 41-6.
10. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin. Proc. 2007; 82: 243-9.
11. Mahon KL, Henshall SM, Sutherland RL etal. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr. Relat. Cancer 2011; 18: R103-23.
12. Guyton AC. Reproductive and hormonal functions of the male. In: Guyton AC (ed.). Textbook of Medical Physiology, 8th edn. WB Saunders Company, Philadelphia, PA, 1991; 885-98.
13. Sharma OP, Weinbauer GF, Behre HM, Nieschlag E. The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate. Urol. Res. 1992; 20: 317-21.
14. Princivalle M, Broqua P, White R etal. Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J. Pharmacol. Exp. Ther. 2007; 320: 1113-18.
15. Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. 2004; 5: 2171-9.
16. Van Poppel H, Tombal B, de la Rosette JJ etal. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-year, multicentre, randomised, phase II dose-finding study in the treatment of prostate cancer. Eur. Urol. 2008; 54: 805-15.
17. Gittelman M, Pommerville PJ, Persson BE etal. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J. Urol. 2008; 180: 1986-92.
18. Klotz L, Boccon-Gibod L, Shore ND etal. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102: 1531-8.
19. Crawford ED, Tombal B, Miller K etal. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 2011; 186: 889-97.
20. McLeod D, Zinner N, Tomera K etal. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-61.
21. Selvaggi F, Khoe GSS, Van Cangh P etal. Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomised, phase III study. Eur. Urol. 2001; 39 (Suppl 5): 78 (abstract #303).
22. Tomera K, Gleason D, Gittelman M etal. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. 2001; 165: 1585-9.
23. Trachtenberg J, Gittleman M, Steidle C etal. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 2002; 167: 1670-4.
24. Plenaxis Drug Information. 2011. [Cited 8 August 2011]. Available from URL:
25. Williams SG, Duchesne GM, Millar JL etal. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60: 1082-7.
26. Hussain M, Tangen CM, Higano C etal. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006; 24: 3984-90.
27. Hussain M, Goldman B, Tangen C etal. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 2009; 27: 2450-6.
28. Tombal B, Miller K, Boccon-Gibod L etal. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 2010; 57: 836-42.
29. Miller K, Rüssel C, Gobel S etal. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). Eur. Urol. Suppl. 2010; 9: 76 (abstract 140).
30. Beer TM, Ryan C, Bhat G etal. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs 2006; 17: 1075-9.
31. Beer TM, Garzotto M, Eilers KM etal. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J. Urol. 2003; 169: 1738-41.
32. Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther. Adv. Urol. 2011; 3: 127-40.
33. Hanninen M, Venner P, North S. A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can. Urol. Assoc. J. 2009; 3: 369-74.
34. Lin GW, Yao XD, Zhang SL etal. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J. Androl. 2009; 11: 443-50.
35. US Food and Drug Administration. 2010. GnRH agonists: label change - increased risk of diabetes and cardiovascular disease (update). [Cited 8 August 2011]. Available from URL:
36. Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J. Urol. 2010; 184: 2313-19.
37. Smith MR, Klotz L, van der Meulen E, Colli E, Tankó L. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analyses of prospective clinical trials of degarelix. J. Urol. 2011; 186: 1835-42.
38. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006; 2: 677-96.
39. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol. Metab. 2009; 20: 43-50.
40. Waknine Y. 2005. International approvals: plenaxis, tostrex, troxatyl. [Cited 8 August 2011]. Available from URL:
41. Specialty European Pharma. 2011. Your partner in urology. [Cited 8 August 2011]. Available from URL:
42. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J. Pharmacol. Exp. Ther. 2002; 301: 95-102.
43. Koechling W, Hjortkjaer R, Tankó LB. Degarelix, a novel gonadotrophin-releasing hormone blocker, causes minimal histamine release in vitro compared with cetrorelix, abarelix and ganirelix. Br. J. Clin. Pharmacol. 2010; 70: 580-7.
44. Schröder FH, Tombal B, Miller K etal. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010; 106: 182-7.
45. Anderson J, Al-Ali G, Wirth M etal. Improved relief of lower urinary tract symptoms (LUTS) with a gonadotrophin-releasing hormone (GnRH) blocker compared with an agonist + antiandrogen (AA) in an open-label, randomised study (CS28). Abstract presented at the European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, 2011.